IV3

ivosidenib


Toggle HydrogenToggle Labels

Chemical Component Summary

Nameivosidenib
SynonymsN-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxo-L-prolinamide
Identifiers(2~{S})-~{N}-[(1~{S})-2-[[3,3-bis(fluoranyl)cyclobutyl]amino]-1-(2-chlorophenyl)-2-oxidanylidene-ethyl]-1-(4-cyanopyridin-2-yl)-~{N}-(5-fluoranylpyridin-3-yl)-5-oxidanylidene-pyrrolidine-2-carboxamide
FormulaC28 H22 Cl F3 N6 O3
Molecular Weight582.961
TypeNON-POLYMER
Isomeric SMILESc1ccc(c(c1)[C@@H](C(=O)NC2CC(C2)(F)F)N(c3cc(cnc3)F)C(=O)[C@@H]4CCC(=O)N4c5cc(ccn5)C#N)Cl
InChIInChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
InChIKeyWIJZXSAJMHAVGX-DHLKQENFSA-N

Chemical Details

Formal Charge0
Atom Count63
Chiral Atom Count2
Bond Count67
Aromatic Bond Count18

Drug Info: DrugBank

DrugBank IDDB14568 
NameIvosidenib
Groups
  • investigational
  • approved
DescriptionIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation.[A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells.[A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.[A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation.[L48781] In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma.[L46287] It was fully approved by the EMA in May 2023.[L46596]
SynonymsIvosidenib
Brand NamesTibsovo
IndicationIvosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor approved for use in the US and Europe. It is indicated for the treatment of patients with a susceptible IDH1 mutation with: - **Newly Diagnosed Acute Myeloid Leukemia (AML)** in combination [azacitidine] or as monotherapy for the treatment of newly diagnosed AML in adults who have comorbidities that preclude the use of intensive induction chemotherapy.[L41870, L46591] this indication is reserved for adults 75 years or older in the US.[L41870] - **Relapsed or refractory AML** in adults in the US.[L41870] - **Locally Advanced or Metastatic Cholangiocarcinoma** in adults who have been previously treated.[L41870, L46591] - **Relapsed or Refractory Myelodysplastic Syndromes** in adults.[L48781]
Categories
  • Amino Acids
  • Amino Acids, Peptides, and Proteins
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Cytochrome P-450 CYP2B6 Inducers
ATC-CodeL01XX62
CAS number1448347-49-6

Drug Targets

NameTarget SequencePharmacological ActionActions
Isocitrate dehydrogenase [NADP] cytoplasmicMSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRD...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inducer
Cytochrome P450 2B6MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG...unknowninducer
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknowninducer
Cytochrome P450 2C8MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...unknowninducer
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682